Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$128.77 USD
+1.38 (1.08%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $128.69 -0.08 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Company Summary
Cambridge, MA-based Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting DMD, a rare genetic disorder affecting children (primarily males). DMD is the most common type of muscular dystrophy.
Sarepta received accelerated approval for its DMD drug, Exondys 51 (eteplirsen), in the United States as a once-weekly intravenous infusion in 2016, specifically targeting patients who have a confirmed mutation of the DMD gene susceptible to exon 51 skipping. Exondys 51 is also Sarepta&...
Company Summary
Cambridge, MA-based Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting DMD, a rare genetic disorder affecting children (primarily males). DMD is the most common type of muscular dystrophy.
Sarepta received accelerated approval for its DMD drug, Exondys 51 (eteplirsen), in the United States as a once-weekly intravenous infusion in 2016, specifically targeting patients who have a confirmed mutation of the DMD gene susceptible to exon 51 skipping. Exondys 51 is also Sarepta’s first PMO-based technology to be granted accelerated approval by the FDA.
Apart from Exondys 51, the company markets three other DMD products. In December 2019, the company received accelerated approval for Vyondys 53 (golodirsen) for treating exon 53 skipping DMD. In February 2021, the company received accelerated approval for Amondys 45 (casimersen) for treating exon 45 skipping DMD. The company is conducting confirmatory studies to gain continued approval for all three drugs.
In June 2023, Sarepta received accelerated approval from the FDA for Elevidys (SRP-9001), the first-ever gene therapy for DMD. Elevidys is currently approved for use in treating ambulatory pediatric patients aged 4 through 5 years with a confirmed mutation in the DMD gene.
The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051, and a Limb-girdle muscular dystrophy (LGMD) candidate, SRP-9003. Sarepta is also developing gene therapies for treating central nervous system (CNS) disorders, including Mucopolysaccharidosis type IIIA (MPS IIIA) and Pompe Disease.
In 2023, the company’s revenues were $1.24 billion, up 33% year over year.
General Information
Sarepta Therapeutics, Inc
215 FIRST STREET SUITE 415
CAMBRIDGE, MA 02142
Phone: 617-274-4000
Fax: 425-354-5038
Email: investors@sarepta.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.11 |
Current Year EPS Consensus Estimate | 2.13 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 5/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 127.39 |
52 Week High | 159.89 |
52 Week Low | 55.25 |
Beta | 0.94 |
20 Day Moving Average | 685,717.94 |
Target Price Consensus | 163.44 |
4 Week | -0.53 |
12 Week | 6.18 |
YTD | 33.54 |
4 Week | 2.48 |
12 Week | 3.24 |
YTD | 24.82 |
Shares Outstanding (millions) | 94.51 |
Market Capitalization (millions) | 12,169.49 |
Short Ratio | NA |
Last Split Date | 7/12/2012 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 60.37 |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 137.90% |
vs. Previous Quarter | 202.17% |
vs. Previous Year | 53.54% |
vs. Previous Quarter | 19.58% |
Price/Book | 14.02 |
Price/Cash Flow | NA |
Price / Sales | 9.79 |
3/31/24 | NA |
12/31/23 | -18.97 |
9/30/23 | -46.23 |
3/31/24 | NA |
12/31/23 | -4.65 |
9/30/23 | -9.69 |
3/31/24 | NA |
12/31/23 | 3.95 |
9/30/23 | 5.44 |
3/31/24 | NA |
12/31/23 | 3.45 |
9/30/23 | 4.90 |
3/31/24 | NA |
12/31/23 | -11.74 |
9/30/23 | -27.23 |
3/31/24 | NA |
12/31/23 | -43.11 |
9/30/23 | -62.52 |
3/31/24 | NA |
12/31/23 | -41.83 |
9/30/23 | -59.89 |
3/31/24 | NA |
12/31/23 | 9.19 |
9/30/23 | 8.17 |
3/31/24 | NA |
12/31/23 | 0.60 |
9/30/23 | 0.62 |
3/31/24 | NA |
12/31/23 | 1.32 |
9/30/23 | 1.62 |
3/31/24 | NA |
12/31/23 | 56.86 |
9/30/23 | 61.80 |